Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.

Autor:	Campani C; Cordeliers Research Center, INSERM, Paris Cité University, 'Functional Genomics of Solid Tumors' Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, Sorbonne Université, Université Paris Cité, Paris, France.; Internal Medicine and Hepatology Unit, Department of Experimental and Clinical Medicine, University of Firenze, Florence, Italy., Imbeaud S; Cordeliers Research Center, INSERM, Paris Cité University, 'Functional Genomics of Solid Tumors' Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, Sorbonne Université, Université Paris Cité, Paris, France., Couchy G; Cordeliers Research Center, INSERM, Paris Cité University, 'Functional Genomics of Solid Tumors' Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, Sorbonne Université, Université Paris Cité, Paris, France., Ziol M; Cordeliers Research Center, INSERM, Paris Cité University, 'Functional Genomics of Solid Tumors' Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, Sorbonne Université, Université Paris Cité, Paris, France.; Pathology Department and Biological Resource Center Center (BB-0033-00027), Paris-Seine-Saint-Denis, University Hospital, Avicenne Hospital, APHP, Sorbonne Paris Nord University, Bobugny, France., Hirsch TZ; Cordeliers Research Center, INSERM, Paris Cité University, 'Functional Genomics of Solid Tumors' Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, Sorbonne Université, Université Paris Cité, Paris, France., Rebouissou S; Cordeliers Research Center, INSERM, Paris Cité University, 'Functional Genomics of Solid Tumors' Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, Sorbonne Université, Université Paris Cité, Paris, France., Noblet B; Cordeliers Research Center, INSERM, Paris Cité University, 'Functional Genomics of Solid Tumors' Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, Sorbonne Université, Université Paris Cité, Paris, France., Nahon P; Cordeliers Research Center, INSERM, Paris Cité University, 'Functional Genomics of Solid Tumors' Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, Sorbonne Université, Université Paris Cité, Paris, France.; Liver Unit, Avicenne Hospital, APHP, University Sorbonne Paris Nord, Bobigny, France., Hormigos K; Cordeliers Research Center, INSERM, CNRS SNC 5096, Sorbonne University, Paris Cité University, Paris, France., Sidali S; Cordeliers Research Center, INSERM, Paris Cité University, 'Functional Genomics of Solid Tumors' Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, Sorbonne Université, Université Paris Cité, Paris, France.; Liver unit, Paris Cité University, Beaujon Hospital, APHP, DMU DIGEST, Clichy, France., Seror O; Cordeliers Research Center, INSERM, Paris Cité University, 'Functional Genomics of Solid Tumors' Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, Sorbonne Université, Université Paris Cité, Paris, France.; Interventional Radiology Unit, Avicenne Hospital, APHP, Bobigny, Paris, France., Taly V; Cordeliers Research Center, INSERM, CNRS SNC 5096, Sorbonne University, Paris Cité University, Paris, France., Ganne Carrie N; Cordeliers Research Center, INSERM, Paris Cité University, 'Functional Genomics of Solid Tumors' Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, Sorbonne Université, Université Paris Cité, Paris, France.; Liver Unit, Avicenne Hospital, APHP, University Sorbonne Paris Nord, Bobigny, France., Laurent-Puig P; Cordeliers Research Center, INSERM, Sorbonne University, Paris Cité University, Institut of Cancer Paris CARPEM, AP-HP-Hôpital Européen Georges Pompidou, Paris, France., Zucman-Rossi J; Cordeliers Research Center, INSERM, Paris Cité University, 'Functional Genomics of Solid Tumors' Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, Sorbonne Université, Université Paris Cité, Paris, France.; Cordeliers Research Center, INSERM, Sorbonne University, Paris Cité University, Institut of Cancer Paris CARPEM, AP-HP-Hôpital Européen Georges Pompidou, Paris, France., Nault JC; Cordeliers Research Center, INSERM, Paris Cité University, 'Functional Genomics of Solid Tumors' Team, Ligue Nationale Contre le Cancer Accredited Team, Labex OncoImmunology, Sorbonne Université, Université Paris Cité, Paris, France naultjc@gmail.com.; Liver Unit, Avicenne Hospital, APHP, University Sorbonne Paris Nord, Bobigny, France.
Jazyk:	angličtina
Zdroj:	Gut [Gut] 2024 Oct 07; Vol. 73 (11), pp. 1870-1882. Date of Electronic Publication: 2024 Oct 07.
DOI:	10.1136/gutjnl-2024-331956
Abstrakt:	Objective: Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC). Design: We analysed 772 plasmas from 173 patients with HCC collected at the time of diagnosis or treatment (n=502), 24 hours after locoregional treatment (n=154) and during follow-up (n=116). For controls, 56 plasmas from patients with chronic liver disease without HCC were analysed. All samples were analysed for cell free DNA (cfDNA) concentration, and for mutations in TERT promoter, CTNNB1 , TP53 , PIK3CA and NFE2L2 by sequencing and droplet-based digital PCR. Results were compared with 232 corresponding tumour samples. Results: In patients with active HCC, 40.2% of the ctDNA was mutated vs 14.6% in patients with inactive HCC and 1.8% in controls (p<0.001). In active HCC, we identified 27.5% of mutations in TERT promoter, 21.3% in TP53 , 13.1% in CTNNB1 , 0.4% in PIK3CA and 0.2% in NFE2L2, most of the times similar to those identified in the corresponding tumour. CtDNA mutation rate increased with advanced tumour stages (p<0.001). In 103 patients treated by percutaneous ablation, the presence and number of mutations in the ctDNA before treatment were associated with higher risk of death (p=0.001) and recurrence (p<0.001). Interestingly, cfDNA concentration and detectable mutations increased 24 hours after a locoregional treatment. Among 356 plasmas collected in 53 patients treated by systemic treatments, we detected mutations at baseline in 60.4% of the cases. In patients treated by atezolizumab-bevacizumab, persistence of mutation in ctDNA was associated with radiological progression (63.6% vs 36.4% for disappearance, p=0.019). In two patients progressing under systemic treatments, we detected the occurrence of mutations in CTNNB1 in the plasma that was subclonal in the tumour for one patient and not detectable in the tumour for the other one. Conclusion: ctDNA offers dynamic information reflecting tumour biology. It represents a non-invasive tool useful to guide HCC clinical management. Competing Interests: Competing interests: PN has received honoraria from and/or consults for AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Gilead, Ipsen and Roche. He received research grants from AstraZeneca, AbbVie, Bristol–Myers Squibb and Eisai. NGC received travel and congress fees, consulting fees or honoraria for lectures, presentations, speakers’ bureaus from Abbvie, Bayer, Gilead, Ipsen, Intercept and Roche. J-CN received research funding from Bayer and Ipsen. CC, SI, GC, MZ, TZH, SR, BN, KH, SS, OS, VT, PL-P and JZ-R have nothing to disclose. (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu